Search Within

Wungki Park

Formats
  1. Meeting Abstract (53)
  2. Journal Article (34)
  3. Review (5)
  4. Correspondence (3)
  5. Editorial (3)
Groups
  1. CTCR Scholars (98)
  2. Center for Pancreatic Cancer Research (98)
  3. Department of Medicine (98)
  4. Gastrointestinal Oncology Service (98)
  5. MSK Grad Students (98)
  6. Master of Science in Clinical and Translational Cancer Research (98)

More Groups

People
  1. Eileen O'Reilly (72)
  2. Anna Varghese (37)
  3. Kenneth Yu (33)
  4. Joanne Chou (25)
  5. William Jarnagin (25)
  6. Alice Wei (23)

More People

Years
  1. 2025 (7)
  2. 2024 (27)
  3. 2023 (18)
  4. 2022 (12)
  5. 2021 (11)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal for ImmunoTherapy of Cancer (9)
  3. Annals of Surgical Oncology (5)
  4. Annals of Oncology (4)
  5. JCO Precision Oncology (4)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (39)
  2. Biomed Central Ltd (9)
  3. Oxford University Press (7)
  4. Springer (7)
  5. Elsevier Inc. (5)
  6. Nature Publishing Group (5)

More Publishers

Results (98)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
    Journal Article

    Sethna, Z.; Guasp, P.; Reiche, C.; Milighetti, M.; Ceglia, N.; Patterson, E.; Lihm, J.; Payne, G.; Lyudovyk, O.; Rojas, L. A.; more...
    Nature (2025)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: Clinical insights and genomic features from a large contemporary cohort
    Journal Article

    Keane, F.; O’Connor, C.; Moss, D.; Chou, J. F.; Perry, M. A.; Crowley, F.; Saxena, P.; Chan, A.; Schoenfeld, J. D.; Singhal, A.; more...
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • Survival outcomes and genetic characteristics of resected pancreatic acinar cell carcinoma
    Journal Article

    Blair, A. B.; Radomski, S. N.; Chou, J.; Liu, M.; Howell, T. C.; Park, W.; O'Reilly, E. M.; Zheng, L.; Balachandran, V. P.; Wei, A. C.; more...
    Annals of Surgical Oncology (2025)

    Fulltext@MSK | Save
  • Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors
    Meeting Abstract

    McIntyre, C. A.; Rudneva, V.; Richards, A. L.; Park, W.; Jarnagin, W. R.; Donoghue, M.; O'Reilly, E. M.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Garrido-Laguna, I.; Wolpin, B. M.; Park, W.; Azad, N. S.; Spira, A. I.; Starodub, A.; Sommerhalder, D.; Punekar, S. R.; Herzberg, B.; Barve, M. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies
    Meeting Abstract

    Thummalapalli, R.; Darmofal, M.; Seier, K.; Khalil, D. N.; Walch, H. S.; Shia, J.; Park, W.; El Dika, I. H.; Chatila, W. K.; Schultz, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository
    Meeting Abstract

    Cowzer, D.; Walch, H. S.; Atri, P.; Shah, F.; Huq, R.; Khalil, D. N.; Park, W.; Yeh, R.; Do, R. K. G.; Basturk, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Nakajima, T.; Moran, D.; Yang, J.; Li, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save